Moderna's revenue has declined post-COVID-19 vaccine success, impacting stock price. However, ongoing clinical progress with mRNA-4157 cancer vaccine shows promise for strong returns in the next five years. Despite recent challenges, the company's pipeline may lead to significant financial gains for patient investors.